These findings indicate that the use of FXR1 inhibitors along with miR301a-3p anti-miR oligonucleotide therapy, combined with chemotherapy, can be a better therapeutic strategy to treat HNSCC patients. Here, FXR1 is linked to head and neck squamous cell carcinoma.